Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Sit Investment Associates Inc.

Sit Investment Associates Inc. decreased its holdings in Moderna, Inc. (NASDAQ:MRNA) by 59.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,409 shares of the company’s stock after selling 10,675 shares during the quarter. Sit Investment Associates Inc.’s holdings in Moderna were worth $308,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRNA. Wilmington Savings Fund Society FSB raised its position in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new stake in Moderna in the fourth quarter valued at $37,000. Venturi Wealth Management LLC boosted its stake in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in Moderna during the 4th quarter worth $41,000. Finally, MassMutual Private Wealth & Trust FSB increased its position in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 2.4 %

Shares of Moderna stock opened at $25.11 on Monday. Moderna, Inc. has a 52 week low of $23.76 and a 52 week high of $170.47. The stock has a market cap of $9.71 billion, a PE ratio of -2.71 and a beta of 2.23. The company’s 50-day moving average price is $33.55 and its two-hundred day moving average price is $42.61.

Analyst Upgrades and Downgrades

MRNA has been the topic of several research analyst reports. Morgan Stanley reduced their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Evercore ISI set a $50.00 target price on Moderna in a research report on Friday, February 14th. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and dropped their price target for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Bank of America decreased their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Friday, March 21st. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Moderna presently has a consensus rating of “Hold” and an average price target of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.